Table 3

Subject	Collection Time (h) ^e	Treatment	Parent / Metabolite(ng/mL)
Subject	Collection Time (h) ^e	Treatment	Donepezil	M1/M2	M4	M6
A	482	Oral	365.1	1.0	5.5	3.6
A	648		118.6	0.9	0.7	0.8
B	482		378.7	2.0	4.8	4.5
B	648		59.3	0.6	0.3	0.1
C	483		248.8	0.9	3.9	5.7
C	648		104.9	0.6	0.8	trace
D	482		456.3	0.7	7.1	6.6
D	636		155.1	0.6	1.1	0.4
E	482		369.6	2.3	3.0	3.9
E	648		91.3	0.7	trace	trace
F	482		369.6	1.9	5.1	7.1
F	648		77.6	0.8	0.8	0.7
G H H	156	7 Day Patch	410.7	0.8	4.8	2.0
G H H	336		182.5	1.2	1.2	0.3
H	180		273.8	0.4	2.4	2.5
H	336		109.5	0.8	0.8	trace
I	156		319.4	0.9	2.5	2.2
I	336		110.9	0.7	0.6	0.3
J	120		365.1	0.8	3.2	3.0
J	312		136.9	1.2	0.8	trace
K	120		182.5	1.2	1.4	1.2
K	288		91.3	1.0	0.8	0.2
L	180		136.9	3.4	0.3	1.7
L	288		45.6	1.4	1.3	0.2

^ecollection time represents a range of plasma concentrations for each subject

Table 3: Donepezil and Metabolite(s) Concentrations in Human Plasma after Repeated Oral Administration (10 mg tablet) or a Single Transdermal Patch (350 mg).